IMCR Earnings Date: Nov 5, 2026 (Estimated) — Immunocore Holdings plc
NASDAQ · Healthcare · Biotechnology
Updated
When is IMCR's next earnings date?
Immunocore Holdings plc (IMCR) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.17 on revenue of $152.9M.
How did IMCR do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Immunocore Holdings plc posted EPS of -$0.02 versus the -$0.01 estimate, a miss of 200.0%. Revenue was $115.9M against a $148.8M estimate. The stock's 1-day post-earnings move was +3.6%.
How much does IMCR stock move after earnings?
IMCR beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 3.8% (up or down) in the day after earnings.
About Immunocore Holdings plc
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.01 | -0.02 | -200.00% | $115.9M | ❌ Miss | +3.63% | +4.36% | +12.86% |
| 2026-05-06 | Q1 2026 | -0.26 | 0.25 | +196.15% | $106.7M | ✅ Beat | +6.55% | +1.59% | -0.28% |
| 2026-02-25 | Q4 2025 | -0.23 | -0.60 | -160.87% | $104.5M | ❌ Miss | -4.51% | -3.92% | -10.10% |
| 2025-11-06 | Q3 2025 | -0.26 | 0.00 | +100.00% | $103.7M | ✅ Beat | +2.58% | +14.58% | +25.91% |
| 2025-02-26 | Q4 2024 | -0.24 | -0.47 | -95.83% | $84.1M | ❌ Miss | +5.34% | +0.14% | +0.89% |
| 2024-05-08 | Q1 2024 | -0.36 | -0.49 | -36.11% | $70.5M | ❌ Miss | +0.46% | -8.50% | -30.06% |
| 2024-02-28 | Q4 2023 | -0.28 | -0.40 | -42.86% | $70.2M | ❌ Miss | -1.76% | -7.65% | -9.75% |
| 2023-11-07 | Q3 2023 | -0.33 | 0.04 | +112.12% | $62.9M | ✅ Beat | +5.71% | +4.32% | +10.76% |
Showing last 8 quarters.
Revenue by segment & region
By region
Q2 FY26 · $115.9M total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 64.6% | $74.9M | +16.9% | $57.3M | $56.6M | $64.1M | $67.3M |
| Europe | 29.4% | $34.1M | +3.3% | $21.1M | $32.8M | $33.0M | $33.5M |
| Rest of World | 5.9% | $6.9M | +722.3% | $1.9M | — | $835K | $2.9M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.